We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
-0.07%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$19.1B
AUM Growth
-$4.04B
Cap. Flow
-$3.24B
Cap. Flow %
-16.98%
Top 10 Hldgs %
50.33%
Holding
204
New
48
Increased
30
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
EA
Electronic Arts
EA
+$492M
2
AVGO icon
Broadcom
AVGO
+$292M
3
KKR icon
KKR & Co
KKR
+$280M
4
ROIV icon
Roivant Sciences
ROIV
+$248M
5
MA icon
Mastercard
MA
+$138M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 46.53%
2 Communication Services 11.31%
3 Financials 11.23%
4 Technology 10.28%
5 Consumer Discretionary 4.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PACB icon
151
Pacific Biosciences
PACB
$357M
$178K ﹤0.01%
135,000
– –
SLS icon
152
SELLAS Life Sciences
SLS
$2.58B
$169K ﹤0.01%
+40,000
New +$179K
ADPT icon
153
Adaptive Biotechnologies
ADPT
$3.94B
$153K ﹤0.01%
11,000
– –
OCUL icon
154
Ocular Therapeutix
OCUL
$2.2B
$152K ﹤0.01%
18,000
– –
NEO icon
155
NeoGenomics
NEO
$2.05B
$141K ﹤0.01%
19,000
– –
ARDX icon
156
Ardelyx
ARDX
$1.05B
$138K ﹤0.01%
23,000
– –
OSCR icon
157
Oscar Health
OSCR
$10.1B
$126K ﹤0.01%
11,000
-253,000
-96% -$3.56M
NUVB icon
158
Nuvation Bio
NUVB
$2.18B
$124K ﹤0.01%
29,000
– –
IOVA icon
159
Iovance Biotherapeutics
IOVA
$3.16B
$91.3K ﹤0.01%
26,000
– –
SLDPW icon
160
Solid Power Inc Warrant
SLDPW
$8.39M
$88.4K ﹤0.01%
405,316
– –
ALT icon
161
Altimmune
ALT
$572M
$85K ﹤0.01%
27,600
– –
CCCC icon
162
C4 Therapeutics
CCCC
$522M
$73.6K ﹤0.01%
28,000
– –
TVRD
163
Tvardi Therapeutics
TVRD
$23.7M
$68.2K ﹤0.01%
21,438
-21,787
-50% -$85.4K
GERN icon
164
Geron
GERN
$943M
$64.1K ﹤0.01%
43,000
– –
BGLWW
165
Blue Gold Ltd Warrant
BGLWW
$748K
$60K ﹤0.01%
300,000
– –
RANI icon
166
Rani Therapeutics
RANI
$89.5M
$57.3K ﹤0.01%
78,000
– –
IRWD icon
167
Ironwood Pharmaceuticals
IRWD
$712M
$45.6K ﹤0.01%
13,000
– –
EVH icon
168
Evolent Health
EVH
$529M
$31.9K ﹤0.01%
14,000
– –
CGC
169
Canopy Growth
CGC
$431M
$28.5K ﹤0.01%
30,000
– –
NVNIW
170
Nvni Group Limited Warrants
NVNIW
$597K
$17.8K ﹤0.01%
375,000
– –
BYND icon
171
Beyond Meat
BYND
$6.95B
$13.3K ﹤0.01%
633
– –
ACLX
172
DELISTED
Arcellx
ACLX
– –
-4,000
Closed -$261K
ALNY icon
173
PUT
Alnylam Pharmaceuticals
ALNY
$30.6B
– –
-100,000
Closed -$39.8M
ASND icon
174
Ascendis Pharma A/S
ASND
$16.3B
– –
-1,400
Closed -$299K
CBRE icon
175
CBRE Group
CBRE
$44.3B
– –
-983,771
Closed -$158M
5 6
7
8 9

Similar funds

VARA
Value Aligned Research Advisors Princeton, New Jersey $20.7B AUM 292.88% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
NAM
Nissay Asset Management Tokyo, Japan $18.9B AUM 27.21% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 204 positions worth $19.1B, down 17% from $23.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Farallon Capital Management withdrew a net $3.24B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 41% a quarter earlier, followed by Communication Services and Financials.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Electronic Arts in Q1 2026, an estimated $492M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 50% of its $19.1B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 17% quarter-over-quarter to $19.1B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.